Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.59 |
| ▸ | CMA1 | P23946 | 7/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22209365 | 0.94 | MALT1 (0.64) | MALT1CMA1EPHA2 | |
| SCHEMBL22811073 | 0.94 | MALT1 (0.64) | MALT1CMA1EPHA2 | |
| SCHEMBL18619572 | 0.94 | MALT1 (0.64) | MALT1CMA1EPHA2 | |
| SCHEMBL18621052 | 0.94 | MALT1 (0.64) | MALT1CMA1EPHA2 | |
| SCHEMBL18619579 | 0.92 | MALT1 (0.61) | MALT1CMA1EPHA2 | |
| SCHEMBL22209378 | 0.92 | MALT1 (0.61) | MALT1CMA1EPHA2DPP4DPP8 | |
| SCHEMBL22209379 | 0.91 | MALT1 (0.61) | MALT1CMA1EPHA2 | |
| SCHEMBL22209464 | 0.91 | MALT1 (0.57) | MALT1CMA1EPHA2ACEDPP4 | |
| SCHEMBL22209394 | 0.90 | MALT1 (0.60) | MALT1CMA1EPHA2 | |
| SCHEMBL18619548 | 0.90 | MALT1 (0.60) | MALT1CMA1EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2017040304-A1 | MALT1 INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711036-B2 | MALT1 inhibitors and uses thereof | MALT1, BCL3, BCL6 | MALT1 1/4885CMA1 130/4885TGM2 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.